GH Research (NASDAQ:GHRS) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald began coverage on shares of GH Research (NASDAQ:GHRS) in a research report issued on Thursday, MarketBeat reports. The firm set an “overweight” rating and a $14.00 price target on the stock. Cantor Fitzgerald’s price objective indicates a potential downside of 2.17% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Monday, January 27th. Canaccord Genuity Group decreased their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th.

GH Research Stock Performance

Shares of GHRS stock opened at $14.31 on Thursday. The stock has a market cap of $744.55 million, a price-to-earnings ratio of -18.11 and a beta of 0.93. The stock has a 50-day moving average of $9.62 and a 200-day moving average of $9.12. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50.

Institutional Investors Weigh In On GH Research

Institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. boosted its position in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after purchasing an additional 85,000 shares in the last quarter. Northern Trust Corp boosted its position in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock valued at $508,000 after purchasing an additional 3,092 shares in the last quarter. AdvisorShares Investments LLC boosted its position in shares of GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares in the last quarter. Finally, Lynx1 Capital Management LP boosted its position in shares of GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).